Initiation of coverage by Edison Investment Research
Quantum Genomics (Alternext - FR0011648971 - ALQGC), a biopharmaceutical company with the mission of developing new therapies for unsatisfied medical needs in the field of cardiovascular diseases, today announces that Edison Investment Research, an international leading independent investment research company, has just initiated coverage of Quantum Genomics with an initiation note entitled « The next generation of cardiac drugs ».
Edison's initiation note is available on the company's website, www.quantum-genomics.com, in the Equity research section of the Investors tab, which already includes Aurgalys and Invest Securities' ones.
Click here to download Edison's initiation note
CONTACTS
Quantum Genomics
Lionel Ségard
Chairman & Chief Executive Officer
+33 1 85 34 77 77
Quantum Genomics
Marc Karako
CFO – Investor Relations
+33 1 85 34 77 75
[email protected]
ACTUS finance & communication (Europe)
Jean-Michel Marmillon
Press Relations
+33 1 53 67 36 73 / [email protected]
The Ruth Group (U.S.)
Lee Roth / Kirsten Thomas
Investor / Public Relations
+1 646-536-7012 / +1 508-280-6592
ABOUT QUANTUM GENOMICS
Quantum Genomics is a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, especially hypertension and heart failure.
The Company is developing a new therapeutic approach based on BAPAI (Brain Aminopeptidase A Inhibition). This is the result of more than 20 years of academic research in the laboratories of the Collège de France, INSERM, CNRS and the University of Paris Descartes.
Quantum Genomics is listed on the Alternext market in Paris (ISIN code FR0011648971, Ticker ALQGC).
The Company has offices in Paris, France, and New York, NY, USA. For more information, please visit www.quantum-genomics.com.
Regulated information
News releases under ongoing reporting obligations:
- other releases
Full and original press release in PDF:
https://www.actusnews.com/documents_communiques/ACTUS-0-46542-QUANTUM_PR_Edison-coverage_20161129_EN.pdf
Receive by email the next press releases of the company by registering on
www.actusnews.com, it's free
Source: Actusnews
Quantum Genomics S.A. Stock
€0.11
22.730%
